CCR10抗体;CCR10 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CCR10 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of MOLT4 cells using CCR10 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of THP-1 cells using CCR10 mouse mAb (green) and negative control (red).    

  
  

CCR10 (C-C chemokine receptor type 10) is a G protein-coupled receptor (GPCR) that binds specific chemokines, primarily CCL27 (cutaneous T-cell-attracting chemokine) and CCL28. It plays a critical role in regulating immune cell trafficking, particularly in skin and mucosal tissues. Expressed predominantly by subsets of T cells, dendritic cells, and epithelial cells, CCR10 facilitates lymphocyte homing to barrier surfaces, contributing to immune surveillance and inflammatory responses. Research has highlighted its involvement in pathologies such as inflammatory skin disorders (e.g., psoriasis, atopic dermatitis), gastrointestinal inflammation, and cancer metastasis, where CCR10-mediated signaling may promote tumor cell migration.

CCR10 antibodies are essential tools for studying receptor expression, ligand interactions, and functional roles in vitro and in vivo. They enable detection of CCR10 on cell surfaces, blockade of ligand binding to investigate signaling pathways, and assessment of therapeutic targeting potential. Recent studies explore CCR10 antibodies as potential therapeutics to modulate immune responses in autoimmune diseases or to inhibit cancer spread. However, complexities in CCR10’s dual roles—balancing protective immunity and pathogenic inflammation—require careful evaluation. Ongoing research aims to clarify its context-dependent functions and optimize antibody-based strategies for clinical applications.